Myriad Genetics Unveils Cutting-Edge Research on Breast Cancer Risk and Treatment at SABCS
SALT LAKE CITY, Dec.9,2024 (GLOBE NEWSWIRE) – Myriad Genetics,Inc. (NASDAQ: MYGN) is set to unveil groundbreaking research at the 2024 San Antonio Breast Cancer Symposium, showcasing advancements in breast cancer risk assessment and molecular residual disease (MRD) detection.
Among the highlights is a spotlight presentation on Myriad’s innovative breast cancer risk assessment tool, which combines a polygenic score applicable across diverse ancestries with traditional risk factors. The presentation, delivered by Dr. Timothy Simmons, Biostatistician III, will delve into longitudinal validation of this tool using the UK Biobank data.
Myriad will also present compelling data on its next-generation MRD assay. This second-generation test achieves remarkable sensitivity, specificity, and accuracy, paving the way for enhanced resolution in detecting residual disease and extending lead times in recurrence detection, according to Dr. George Daneker, President and Chief Clinical Officer, Oncology at Myriad Genetics.
"We’re thrilled to share these validation results at SABCS, a premier platform for showcasing clinical applications in early and advanced breast cancer,” said Dr. Daneker. “Myriad stands out as one of the few labs offering complete germline and tumor genomic testing, complemented by customizable workflows, point-of-care patient education, and clinically focused reports. Our groundbreaking test results are fortified by concordance checks between germline and tumor genomic findings and actionable insights summarized for easy interpretation by healthcare professionals.”
Myriad Genetics Data Presentations
- Spotlight Presentation: Session 16, PS16-01: Polygenic Risk
- Date/Time: Thursday, Dec. 12,2024,5:30-7:00 pm (CST),Hemisfair Ballroom 3
- Presenter: Timothy Simmons,PhD,Biostatistician III,Myriad Genetics
- Rapid-Fire Presentation: RF1-06
- Date/Time: Wednesday,Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1
- Presenter: Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics
- Poster Presentation: P2-04-23
- Date/Time: Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3
- Presenter: Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics
Poster Presentation: P3-02-10
- Date/Time: Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3
- Presenter: holly Pederson, MD, Cleveland Clinic
Beyond these presentations, Myriad invites attendees to visit booth (#1327) where they can explore its latest offerings,
including:
MyRisk® Hereditary Cancer Test: This comprehensive test evaluates 48 genes linked to 11 hereditary cancers, providing clear, actionable results for personalized care.
MyRisk with RiskScore®: This advanced version of MyRisk offers an in-depth, personalized assessment of five-year and lifetime breast cancer risks.
Precise Tumor® Molecular Profile Test: This comprehensive genomic profiling test provides insights into a wide range of solid tumors, aiding oncologists in interpreting results, prioritizing therapies, and taking personalized next steps for patient care.
mychoice® CDx: A groundbreaking homologous recombination deficiency (HRD) test enabling precise identification of tumors with impaired double-stranded DNA repair mechanisms, making them vulnerable to targeted therapies such as platinum drugs and PARP inhibitors.
- EndoPredict® Breast Cancer Prognostic Test: This test provides valuable prognostic information for patients with ER+, HER2-, node negative or node positive breast cancer, guiding tailored treatment decisions.
About Myriad Genetics Myriad Genetics is a pioneering company in genetic testing and precision medicine dedicated to improving health and well-being for all. We develop and deliver genetic tests that assess the risk of disease progression, guide treatment decisions, and have a profound impact on patient care and healthcare costs across various medical specialties where genetic insights are essential.More information is available at www.myriad.com.
What are the key advancements in breast cancer risk assessment tools developed by Myriad Genetics?
Interview Between Time.news Editor and Dr. Timothy Simmons, Biostatistician III at Myriad Genetics
Editor: Good morning, Dr.Simmons. Thank you for joining us today as we discuss the exciting research myriad Genetics is unveiling at the San Antonio Breast Cancer Symposium. Let’s jump right in. Can you tell us about the new breast cancer risk assessment tool you’ll be presenting?
Dr. Simmons: Good morning! It’s great to be here. Our new breast cancer risk assessment tool represents a significant leap forward in how we evaluate risk. Traditionally, risk assessments focused on family history and other singular factors, but our approach integrates a polygenic score that can be applied across diverse ancestries, along with conventional risk factors. This allows for a more comprehensive understanding of an individual’s risk profile.
Editor: That sounds fascinating! How does the polygenic score function, and why is it crucial for diverse populations?
Dr. Simmons: the polygenic score is derived from genetic variants that have been associated with breast cancer. By incorporating this score, we can provide a personalized risk assessment that acknowledges the genetic diversity in the population. This is especially critically important for underrepresented groups, as it ensures that we are not just relying on a one-size-fits-all model, but rather offering insights that cater to different ancestral backgrounds.
Editor: That definitely sounds like a step in the right direction. You mentioned validating this tool using UK Biobank data. What does that process entail, and what were your findings?
Dr. Simmons: Validation is a critical component of our research. By using the extensive dataset from the UK biobank, which includes comprehensive health records and genetic information from hundreds of thousands of individuals, we are able to assess the predictive power and accuracy of our tool. The initial findings are promising,showing that our risk assessment can effectively stratify individuals into high and low-risk categories with a good degree of accuracy.
Editor: That’s impressive! Moving on to your next-generation MRD assay, could you explain what MRD detection is and why it’s vital in oncology?
Dr. Simmons: Absolutely! Minimal Residual Disease (MRD) detection is essential for identifying small numbers of cancer cells that may remain post-treatment and could lead to recurrence. Detecting MRD early can significantly influence treatment decisions and patient outcomes. Our next-generation assay boasts remarkable sensitivity, specificity, and accuracy, meaning we can detect residual disease much earlier than before, giving clinicians and patients a better chance at prosperous management.
Editor: How exactly does this next-generation assay improve upon previous methods?
Dr. Simmons: Previous methods for MRD detection had limitations in sensitivity,leading to potential false negatives or delays in recurrence detection. Our second-generation assay has been engineered for higher sensitivity and specificity, which means a better chance of catching residual disease before it manifests as a recurrence. This not only provides peace of mind but allows for more proactive measures in patient management.
Editor: That’s groundbreaking! With these advancements, what do you envision for the future of breast cancer diagnosis and treatment?
Dr. Simmons: I’m optimistic about a more individualized approach moving forward. Innovations like ours are paving the way for precision oncology, where treatments are tailored to the specific biological and genetic characteristics of each patient.This can transform outcomes by ensuring that patients receive the right treatment at the right time.
Editor: Thank you, Dr. Simmons, for sharing these insights! It sounds like Myriad Genetics is leading the charge in transforming breast cancer assessment and treatment. We’re excited to see the results of your presentations at SABCS.
Dr. Simmons: Thank you for having me! I look forward to sharing our findings with the broader oncology community and ultimately improving patient outcomes in breast cancer.